ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 0074 • ACR Convergence 2025

    Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

    Sophie Hopkin1, Kathryn Malpas1, David Kallenberg1, Jacqueline O'Neill1, Geofrey Odede1, Kerry Tyson1, Sue Cross1, Tatiana SOKOLOVA2, Bernard Lauwerys3, Baran Ufuktepe4, Patrick Durez5, Susanna Bidgood1 and David Humphreys1, 1UCB Pharma, Slough, England, United Kingdom, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 3Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, 4UCB Pharma Istanbul, Turkey, istanbul, Turkey, 5Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…
  • Abstract Number: 2261 • ACR Convergence 2025

    Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India

    Sryla Punjadath1, Venkatesh Srinivasa Pai1, Prativa Priyadarshani Sethi1, ritu sangwan2, Abhishek Rai3 and Ravi Kant1, 1All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, 2AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, 3AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India

    Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
  • Abstract Number: 0073 • ACR Convergence 2025

    HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

    S. Janna Bashar1, Courtney Myhr1, Adam Titi1, Zihao Zheng1 and Miriam Shelef2, 1University of Wisconsin-Madison, Madison, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
  • Abstract Number: 2248 • ACR Convergence 2025

    Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study

    Margaret Ma1, Khai Pang Leong2, ee tzun koh2, Preeti Dhanasekaran3, janique peyper4, bermet abylova4, Anselm Mak3 and Peter Cheung1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Standard BioTools, Singapore, Singapore

    Background/Purpose: Autoantibody-based biomarkers including ACPA and RF are of established clinical use in rheumatoid arthritis (RA) and are ingrained in international classification criteria. However, other…
  • Abstract Number: 2231 • ACR Convergence 2025

    Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)

    Anne-Christine Bay-Jensen1, Dovile Sinkeviciute2, Christian Thudium2, shu Sun1, Mathilde Christensen1, Morten Karsdal1, marta Alexdottir1 and Joachim mortensen1, 1Nordic Bioscience A/S, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Neutrophils are crucial in fibro-inflammatory diseases like Crohn's disease (CD) and rheumatoid arthritis (RA), but their biomarkers are better established in CD than in…
  • Abstract Number: 1427 • ACR Convergence 2024

    Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study

    Sophia G. Liva1, fudan Zheng1, Jocelyn H. Leu2, Kathy Sivils3, Keying Ma1, He Li4, Steven Leonardo5, Kim Lo1, Jada Idokogi1, Kim Campbell1 and Jonathan J. Hubbard1, 1Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Johnson & Johnson Innovative Medicine, Edmond, OK, 4Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
  • Abstract Number: 2210 • ACR Convergence 2024

    Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality

    Rebecca Brooks1, Sara Achenbach2, Vanessa Kronzer1, Elena Myasoedova1, Cynthia Crowson1 and John Davis1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how…
  • Abstract Number: 2212 • ACR Convergence 2024

    Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort

    Rodrigo Garcia Salinas1, Felicia Almada2, Gisel Reyes-Jara2, Ronald Perez-Andocillas2 and Sebastian Magri3, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano La Plata, Melchor Romero, Argentina

    Background/Purpose: To estimate the frequency of seropositive arthralgia (SA) in a large cohort of patients evaluated for arthralgia in Reuma-check program. To compare the features…
  • Abstract Number: 2213 • ACR Convergence 2024

    Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis

    Vanshika Sabharwal, and Dr Ashit syngle and Dr Inderjeet Verma, MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India

    Background/Purpose: RA is a chronic inflammatory disease associated with an excessive premature cardiovascular morbidity and mortality. Endothelial dysfunction is a significant contributor to CVD in…
  • Abstract Number: 2233 • ACR Convergence 2024

    Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Susan Manzi5, Michael Mahler6, Veena Joy7 and Tyler O'Malley8, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Werfen, San Diego, CA, 7ThermoFisher, Philadelphia, PA, 8Exagen, Vista, CA

    Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
  • Abstract Number: 0055 • ACR Convergence 2024

    Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis

    Katharine moosic1, Thomas Olson2, Mark Freijat3, samara khalique4, Cait Hamele1, Bryna Shemo1, Jesse Boodoo5, William Baker6, Gitanjali Khurana7, Matthew Schmachtenberg8, Tristin Duffy8, Aakrosh Ratan1, Erika Darrah9, Felipe Andrade10, Marieke Jones8, Kristine Olson2, David Feith1, Thomas Loughran1 and Donald Kimpel1, 1University of Virginia, Charlottesville, VA, 2Virginia Commonwealth University, Richmond, VA, 3Flow Rheumatology, Scottsdale, AZ, 4Carilion Clinic/ VirginiaTech, Salem, VA, 5Sarasota Arthritis Center, Sarasota, FL, 6Atrium Health, Charlotte, NC, 7University of Virginia, CROZET, VA, 8University of Virginia, Charlottesville, 9Johns Hopkins University, Baltimore, MD, 10The Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
  • Abstract Number: 2250 • ACR Convergence 2024

    Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity

    Elena Joerns1, Ryan Lennon2, Cynthia Crowson2, Andrea Lopez-ruiz2, Roslin Jose George2, Vanessa Kronzer2, John Davis2 and Elena Myasoedova2, 1Mayo Clinic, Rochester, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
  • Abstract Number: 0059 • ACR Convergence 2024

    Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance

    Susanna R. Bidgood1, Sophie Hopkin1, Kathryn R. Malpas1, David M. Kallenberg1, Jacqueline O’Neill1, Geofrey Odede1, Bernard Lauwerys2, Baran Ufuktepe3 and David Humphreys1, 1UCB Biopharma UK, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Istanbul, Turkey

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
  • Abstract Number: 2266 • ACR Convergence 2024

    Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis

    Michael George1, Kelly Gavigan2, Shilpa Venkatachalam3, David Curtis2, Laura Stradford4, William Benjamin Nowell5, Fenglong Xie6, Joshua Baker1 and Jeffrey Curtis7, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, New York, NY, 4Global Healthy Living Foundation, Nyack, NY, 5Regeneron, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…
  • Abstract Number: 0158 • ACR Convergence 2024

    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023

    Karis Lee1, Min Kyung Lee2, David Alfego3, Kristen Clark4 and Stanley Naides5, 1Labcorp, Orlando, FL, 2Labcorp, San Diego, CA, 3Labcorp, Carlsbad, CA, 4Labcorp, Raleigh, NC, 5Labcorp, Dana Point, CA

    Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology